ӳ����ý

We have developed the Rapid Automated Binder Identification Technology (RABIT) platform, which enables the cost-effective identification of varied sets of biological “binders,” including camelid nanobodies, human VHH domains, and single-chain fragments (scFv). , the RABIT platform identifies binders with varied epitopes and affinities against protein and peptide targets. This fully automated process allows for rapid execution on parallel targets or selection strategies.

The identification of binders with varied epitopes and affinities is crucially important for many different applications, including the development of:

• bispecific or biparatopic therapeutic antibodies 
• novel multivalent biologics
• CAR-T therapies
• novel affinity reagents for many different imaging and diagnostic applications